Cohen Cheryl sold $1.2M of IBRX
Cohen Cheryl sold 131,210 shares of ImmunityBio, Inc. (IBRX) at $9.50 ($1.25M total) on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure quantifies the sale size ($1.25M) and confirms it was executed via an open-market sale under a pre-arranged 10b5-1 plan, which generally limits inference about new negative information.
Market read
Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a major repricing without accompanying fundamental news.
What to watch
The article provides no context on total insider holdings beyond post-transaction shares, no stated rationale, and no linkage to company fundamentals; impact should be treated as sentiment-only.
Background
This is an SEC Form 4 insider transaction for ImmunityBio, Inc. (IBRX) by director Cheryl Cohen.
Ticker impact
Director Cheryl Cohen filed a Form 4 open-market sale of 131,210 shares at $9.5034 on 2026-07-02 under a 10b5-1 plan.
Likely limited near-term price impact; any effect should be small and short-lived unless followed by additional disclosures.
Form 4 details a planned open-market sale with a 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative signal about near-term risk/reward.
Key entities
- issuerImmunityBio, Inc.
Subject of the Form 4 insider transaction; director Cheryl Cohen sold shares under a 10b5-1 plan.
- insiderCheryl Cohen
Director who executed the open-market sale of 131,210 shares.
